Indian Markets Feel the Heat as S&P 500 Posts Worst Week Since Iran War
The S&P 500’s worst week since the Iran war began has sent shockwaves through global markets, including India. What does this mean for Nifty and Sensex investors?
Your blog category
The S&P 500’s worst week since the Iran war began has sent shockwaves through global markets, including India. What does this mean for Nifty and Sensex investors?
The S&P 500 has closed out its worst week since the Iran war began, marking its fifth consecutive losing week. What does this mean for Indian investors and the domestic market?
KBRA’s latest research examines the impact of artificial intelligence on software and private credit portfolios, highlighting manageable credit risks and potential pressure on sponsor-backed borrowers.
As New York City prepares to host the 2026 FIFA World Cup, a debate over short-term rentals has sparked a discussion on housing stability and economic benefits. What can Indian investors learn from this dilemma?
Discover how Ford’s AI-driven approach to scaling dealer analysis is transforming the Indian automotive industry, and what it means for investors and traders.
The US stock market has witnessed its worst week since the Iran war began, with the S&P 500 falling 1.7%. What does this mean for Indian investors and global market trends?
A groundbreaking nasal swab test developed by Duke Health researchers can detect early biological signals of Alzheimer’s disease, offering new hope for Indian patients and their families.
The Union government introduces the Jan Vishwas Bill to decriminalise minor offences, aiming to promote ease of doing business and improve the overall business environment in India.
Vera Therapeutics has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). Here’s what Indian investors should know about the company and its prospects.
NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., has signed a third amendment to its existing License Agreement with MOA Life Plus Co. Ltd., a Korean biotechnology company, to update the timing and key development milestones for EL-32 and EL-22 human clinical development programs.